MichaelYoungjunChoiMD
Hematology • La Jolla, CAHematologic Oncology
Associate Professor, Medicine, UC San Diego Sch. of Medicine
Dr. Choi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3855 Health Sciences Dr
La Jolla, CA 92093Phone+1 858-822-0863Fax+1 858-246-1847- Is this information wrong?
Education & Training
University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012- University of California (San Diego) Medical CenterResidency, Internal Medicine, 2005 - 2008
Keck School of Medicine of the University of Southern CaliforniaClass of 2005
Certifications & Licensure
CA State Medical License 2007 - 2024- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Young Investigator Award Tower Cancer Research Foundation, 2012
Clinical Trials
- UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia Start of enrollment: 2014 Aug 08
- Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL Start of enrollment: 2016 Jun 01
- Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome Start of enrollment: 2017 Dec 20
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsMetastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells.Botta, G., Chao, J., Ma, H., Hahn, M., Sierra, G., Jia, J., Hendrix, A., Nolte Fong, J., Ween, A., Vu, P., Miller, A., Choi, M., Heyman, B., Daniels, G., Kaufman, D., ...> ;Journal for Immunotherapy of Cancer. 2024 Feb 5
- Novel BRAF N581S mutation in mantle cell lymphoma.Heyman, B., Hariharan, N., Bedi, D., Choi, M., Wang, H.> ;Ejhaem. 2024 Feb 1
- A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter's Transformation.Benjamin Heyman, Michael Choi, Thomas J Kipps> ;Case Reports in Hematology. 2024 Jan 1
- Join now to see all
Abstracts/Posters
- Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...Michael Y. Choi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...Michael Y. Choi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular TherapiesMichael Y. Choi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Phase 1/2 trial of cirmtuzumab and ibrutinib: Planned analysis of phase 1 CLL cohorts.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual MeetingDecember 9th, 2019
Oncternal Therapeutics Announces Updated Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with IbrutinibJune 3rd, 2019
Oncternal Therapeutics to Present Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib at the 2019 American Society of Clinical Oncology Annual MeetingMay 15th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
